Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Refractory AIDS-Related Kaposi's Sarcoma
NCT00005931Phase 2Completed
- Sponsor
- Sugen Inc.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaxanib, sponsored by Sugen Inc. Primary endpoint: Tumor Response (Clinical and/or Radiographic). Status: completed.
02
Drugs
semaxanib
Beyond the preview
Go deeper on NCT00005931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005931.